Replies to post #457856 on Anavex Life Sciences Corp (AVXL)

[boi568]

ANVS reported on a subset n of 90 using criteria that had not been pre-specified. So no, not pivotal, and not analogous to our 2b/3, either.

[frrol]

From their results, they certainly need another trial to progress in AD. A lot of hair on their TLR; they had to do heavily ad hoc analysis to tease out a potential efficacy signal. They too failed in ADCS and are arguing that this endpoint battery wasn't expected to be significant.

At least from present disclosures, our trial and results appear better than Annovis on almost all counts. (Not an approval factor of course.)